Apricus Biosciences Reports Additional Analysis Showing That MycoVa(TM) is as Effective for the Treatment of Nail Fungus as the Current European Standard of Care for Topical Therapy, Loceryl(R)

SAN DIEGO, Jan. 19, 2011 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio") (Nasdaq:APRI) today announced that an additional analysis conducted on behalf of the Company has shown that MycoVa™ has successfully demonstrated 'non-inferiority' for the treatment of onychomycosis (commonly referred to as nail fungus), compared to the current standard of care in Europe for topical therapy, Loceryl®.